Ige Antibodies
Ige Antibodies - Related Videos
09:40
Detection of True IgE-expressing Mouse B Lineage Cells
0 Views •
Cited by 3 •
2014
In vitro analysis of class switch recombination in mice is challenging due to cytophilic IgE molecules bound to Fc receptors on the surface of B cells. We describe a method for IgE detection using trypsin-mediated cleavage of surface-bound IgE prior to fixation and permeabilization for cytoplasmic fluorescence staining.
10:22
Basophil Activation Test for Investigation of IgE-Mediated Mechanisms in Drug Hypersensitivity
0 Views •
Cited by 14 •
2011
Basophil activation test is a potent tool for the detection of IgE-dependent allergies in vitro. Here, an optimized protocol for basophil activation test is used to investigate drug hypersensitivity. A method for the efficient production of covalent drug-protein conjugates and their physicochemical characterization is described.
13:21
Antibody Generation: Producing Monoclonal Antibodies Using Hybridomas
0 Views •
2023
Source: Frances V. Sjaastad1,2, Whitney Swanson2,3, and Thomas S. Griffith1,2,3,4 1 Microbiology, Immunology, and Cancer Biology Graduate Program, University of Minnesota, Minneapolis, MN 55455 2 Center for Immunology, University of Minnesota, Minneapolis, MN 55455 3 Department of Urology, University of Minnesota, Minneapolis, MN 55455 4 Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455 Polyclonal antibodies are defined as a collection of antibodies directed against...
01:25
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
0 Views •
2024
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed. Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:10
Antibody Structure
0 Views •
2019
Overview Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding. The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains Antibodies consist of four polypeptide chains: two identical heavy...
FAQs
Allergen-mediated cross-linking brings neighboring IgE-bound FcεRI receptors into an activating arrangement on mast cells and basophils. This receptor engagement initiates rapid degranulation, followed by release of several inflammatory mediators. The resulting chemical response explains why allergic effects can develop quickly and include airway narrowing, itching, and localized or broader tissue swelling.
FcεRI functions as the high-affinity receptor that positions IgE on mast cells and basophils before allergen exposure. Its strong interaction with IgE allows these cells to respond when an allergen links receptor-associated IgE molecules. In pharmacology, this receptor-centered mechanism provides a logical point for reducing downstream inflammatory activation.
Degranulation releases histamine, leukotrienes, and other inflammatory mediators rather than producing a single uniform effect. Together, these substances can affect airway caliber, sensory symptoms, and vascular or tissue responses, leading to bronchoconstriction, itching, and swelling. Linking mediator release with clinical effects helps interpret the physiological consequences of IgE activation.
Anti-IgE biologics are designed to reduce the amount or activity of IgE available to support receptor activation. By weakening the pathway that connects allergen recognition with mast-cell and basophil responses, these treatments can help control IgE-associated inflammation. Their use illustrates how pharmacology can target an upstream immune signal rather than only individual symptoms.
Allergy testing is relevant because it helps investigate immune responses associated with particular allergens. In the context of IgE antibodies, test findings can support evaluation of allergic sensitivity and help connect suspected exposures with clinical symptoms. This information contributes to treatment planning and to research aimed at developing more selective interventions.
IgE responses also contribute to host defense against certain helminths, which are parasitic worms. This protective role shows that IgE signaling is not solely pathological; the same rapid immune machinery associated with allergy can participate in defense. Pharmacological strategies must therefore be understood within both disease-related inflammation and normal immune function.
IgE-focused pharmacology is especially relevant to allergic diseases in which receptor activation and mediator release contribute to symptoms. The overview identifies asthma and urticaria among the conditions addressed by anti-IgE treatment, while allergic disease more broadly motivates allergy testing and therapeutic development. These applications connect molecular signaling with clinically meaningful disease control.